UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Controversies in the treatment of local and locally advanced gastric and esophageal cancers

Journal of clinical oncology, 2015-06, Vol.33 (16), p.1754-1759

2015

Volltextzugriff (PDF)

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.486-493

2023

Volltextzugriff (PDF)

Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma

Expert opinion on pharmacotherapy, 2021-01, Vol.22 (1), p.93-107

2021

Volltextzugriff (PDF)

Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection

Immunotherapy, 2020-04, Vol.12 (5), p.287-292

2020

Volltextzugriff (PDF)

Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?

Expert opinion on pharmacotherapy, 2019-02, Vol.20 (3), p.357-366

2019

Volltextzugriff (PDF)

CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Clinical cancer research, 2014-08, Vol.20 (15), p.3974-3988

2014

Volltextzugriff (PDF)

Harnessing the Microbiome for Pancreatic Cancer Immunotherapy

Trends in Cancer, 2019-11, Vol.5 (11), p.670-676

2019

Volltextzugriff (PDF)

Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Clinical cancer research, 2024-10, Vol.30 (20), p.4803-4803

2024

Volltextzugriff (PDF)

Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition

Hematology/oncology clinics of North America, 2012-06, Vol.26 (3), p.565-588

Cohen, Deirdre J

2012

Volltextzugriff (PDF)

Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy

JAMA network open, 2023-03, Vol.6 (3), p.e234254-e234254

2023

Volltextzugriff (PDF)

An expert opinion on esophageal cancer therapy

Expert opinion on pharmacotherapy, 2011-02, Vol.12 (2), p.225-239

2011

Volltextzugriff (PDF)

Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma

Cancer treatment reviews, 2008-12, Vol.34 (8), p.719-727

2008

Volltextzugriff (PDF)

Targeting the Hedgehog Pathway

Hematology/oncology clinics of North America, 2012-06, Vol.26 (3), p.565-588

Cohen, Deirdre J., MD

2012

Volltextzugriff (PDF)

650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A741-A741

2023

Volltextzugriff (PDF)

RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Clinical cancer research, 2014-08, Vol.20 (15), p.3974-3988

2014

Volltextzugriff (PDF)

Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation

Journal of gastrointestinal oncology, 2018-10, Vol.9 (5), p.922-935

2018

Volltextzugriff (PDF)

Exploring racial disparities and tumor characteristics of CA19-9 producer and non-producer among patients with advanced pancreatic ductal adenocarcinoma (PDAC): Implications for survival and personalized treatment strategies

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16309-e16309

2024

Volltextzugriff (PDF)

Effect of immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC) based on underlying liver disease

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.396-396

2022

Volltextzugriff (PDF)

Postoperative Intraperitoneal 5-Fluoro-2′-Deoxyuridine Added to Chemoradiation in Patients Curatively Resected (R0) for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Annals of surgical oncology, 2012-02, Vol.19 (2), p.478-485

2012

Volltextzugriff (PDF)

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2011-08, Vol.68 (2), p.371-378

2011

Volltextzugriff (PDF)

Tu1911 ADDITION OF ANTIBIOTIC TREATMENT TO GEMCITABINE CHEMOTHERAPY IMPROVES OVERALL SURVIVAL FOR PATIENTS WITH EARLY-STAGE PDAC WHO HAVE UNDERGONE SURGICAL RESECTION

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1466-S-1466

2024

Volltextzugriff (PDF)

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer

Journal of clinical oncology, 2015-04, Vol.33 (12), p.1325-1333

2015

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(159)

Publikationsform

Sprache

Englisch
(186)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Controversies in the treatment of local and locally advanced gastric and esophageal cancers

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment

Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression

Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer

Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?

CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Harnessing the Microbiome for Pancreatic Cancer Immunotherapy

Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer

Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy

An expert opinion on esophageal cancer therapy

Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma

Targeting the Hedgehog Pathway

650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer

RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation

Exploring racial disparities and tumor characteristics of CA19-9 producer and non-producer among patients with advanced pancreatic ductal adenocarcinoma (PDAC): Implications for survival and personalized treatment strategies

Effect of immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC) based on underlying liver disease

Postoperative Intraperitoneal 5-Fluoro-2′-Deoxyuridine Added to Chemoradiation in Patients Curatively Resected (R0) for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

Tu1911 ADDITION OF ANTIBIOTIC TREATMENT TO GEMCITABINE CHEMOTHERAPY IMPROVES OVERALL SURVIVAL FOR PATIENTS WITH EARLY-STAGE PDAC WHO HAVE UNDERGONE SURGICAL RESECTION

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer

Suchergebnisse filtern